📈 Live Market Tracking
Every NSE and BSE corporate filing, read and explained by AI within minutes — impact, key figures, short/long-term view and what to watch.
Live · AI analyzer runs every 5 min (07:00–23:55 IST)
Latest filing: 2026-09-03 13:43
343 analysed today
343
Today
133,232
All-time analysed
40,094
Positive
6,279
Negative
79,048
Neutral
7,743
Watch
📊 Last 7 days — analysed filings by sentiment
Note: These are AI-generated, educational summaries of public NSE
filings — grounded in each document, but not investment advice and possibly incomplete.
Verify against the original filing and consult a SEBI-registered adviser before acting.
41 announcements match the current filters (relevance ≥ 5).
Max Healthcare Adds 400-Bed Tower at Saket, Expanding Facility Capacity to ~1,200 Beds
Max Healthcare has inaugurated a new 400-bed tower at Max Smart Super Speciality Hospital, Saket. This operational expansion increases the Saket facility's total capacity to approximately 1,200 beds, making it the largest private hospital by bed capacity in Delhi. Across its entire network, the company operates 21 healthcare facilities with over 6,100 beds. The new tower enhances high-margin quaternary care capabilities, equipped with surgical robotics like Da Vinci Xi and Mako systems.
Confidence: HIGH
What changedMax Healthcare operationalized a new 400-bed tower at its flagship Saket complex in New Delhi.
Why it mattersSaket is a prime quaternary care hub; adding 400 beds expands network capacity by ~6.5% and supports volume growth in high-ARPOB surgical specialties.
Capacity added: 400 bedsTotal Saket capacity: ~1,200 bedsTotal network capacity: 6,100+ bedsSpecialties covered: 22+
📅 Short termPositive sentiment from capacity commissioning; initial quarters may see operating leverage build up as new beds are gradually staffed and occupied.
📈 Long termDirectly aligns with the company's stated strategy to double bed capacity over 5 years and strengthens its high-margin market position in Delhi-NCR.
⚠ Risk flags
🔬 Flagged for deeper Multibagger analysis — view briefs →
- Geographic concentration in Delhi-NCR
- Initial margin dilution during bed occupancy ramp-up
Key Highlights
Inaugurated a new 400-bed tower at Max Smart Super Speciality Hospital in Saket
Expands total bed capacity at the Saket complex to approximately 1,200 beds
Increases the company's overall operational footprint across 21 facilities with 6,100+ beds
Facility features advanced robotics including Da Vinci Xi and Mako Total Knee Replacement Robot across 22+ specialties
👀 What to Watch
Track occupancy ramp-up speed and ARPOB realization at the new Saket tower over the upcoming quarterly earnings releases.
Max Healthcare Subsidiary Receives ₹165.7 Cr GST Demand and Penalty Notice
Max Healthcare's wholly-owned subsidiary, Alps Hospital Limited, received a show cause cum demand notice from the Directorate General of Goods & Services Tax Intelligence (DGGI), Mumbai Zonal Unit. The notice alleges non-payment of GST on variable management fees, demanding ₹55.24 Cr in unpaid GST plus applicable interest. Additionally, two separate penalties of ₹55.24 Cr each have been proposed, taking the total potential liability to ₹165.71 Cr (excluding interest). This total exposure equals approximately 11.4% of the company's TTM PAT of ₹1,457 Cr. The management is currently preparing submissions to contest the notice.
Confidence: HIGH
What changedAlps Hospital Limited was served a show cause cum demand notice by DGGI Mumbai alleging unpaid GST on variable management fees.
Why it mattersThe combined demand and penalty of ₹165.71 Cr represents about 11.4% of annual net profit (FY26 PAT: ₹1,442 Cr), posing legal and contingent liability risks.
Alleged GST Demand: ₹55,23,52,071Alleged Penalty (Sec 74/74A): ₹55,23,52,071Alleged Penalty (Sec 122): ₹55,23,52,071Total Demand vs TTM PAT: ~11.4%Date of Notice Receipt: August 25, 2026
📅 Short termManagement is preparing legal replies to contest the notice; no immediate cash outflow is required at the show-cause stage.
📈 Long termIf decided unfavorably across appellate stages, it could result in one-time financial provisions and require restructuring of variable management fee arrangements across subsidiaries.
⚠ Risk flags
- Adverse tax adjudication leading to demand confirmation and interest accumulation
- Potential risk of similar GST scrutiny on other group entities if fee structuring is challenged
Key Highlights
Alleged GST demand of ₹55,23,52,071 (₹55.24 Cr) along with applicable interest.
Two proposed penalties of ₹55,23,52,071 each under Section 74(1)/74A(5)(ii) and Section 122(2)(b) of the CGST Act.
Total demanded tax and penalty amount totals ₹165.71 Cr (excluding interest).
Notice received by subsidiary Alps Hospital Limited on August 25, 2026 regarding variable management fees.
👀 What to Watch
Track the subsidiary's legal submissions in response to the show cause notice and watch for subsequent adjudication orders or potential provisioning in upcoming quarterly results.
Max Healthcare Q1 FY27 Call: Revenue Up 16% to ₹2,982 Cr, ₹425 Cr Capex for Vaishali
Max Healthcare reported a 16% YoY increase in Network gross revenue to ₹2,982 crore and a 15% YoY increase in operating EBITDA to ₹704 crore (24.8% margin) for Q1 FY27. Average Revenue Per Occupied Bed (ARPOB) increased 5% YoY to ₹81,900 with network occupancy exceeding 75%. The company approved a ₹425 crore brownfield capex at Max Vaishali (+202 beds) and is progressing on a 500-bed greenfield facility in Gurgaon set for phased commissioning by year-end.
Confidence: HIGH
What changedFiling of the full transcript of the Q1 FY27 earnings conference call detailing capacity rollout timelines and new capex approvals.
Why it mattersDemonstrates sustained operational efficiency with ARPOB expansion and transparent execution on doubling network bed capacity over the next 3-5 years.
Q1 Network Gross Revenue: ₹2,982 croreQ1 Operating EBITDA: ₹704 croreMax Vaishali Capex: ₹425 croreVaishali Capex vs TTM Revenue: ~4.9%ARPOB: ₹81,900Net Debt: ₹2,384 crore
📅 Short termStable sentiment driven by steady operational metrics and clear commissioning schedules across brownfield projects (Smart and Nanavati).
📈 Long termStrong multi-year visibility backed by significant capacity additions across NCR, Mohali, and Lucknow alongside de-risking into new regional clusters.
⚠ Risk flags
- Temporary margin dilution from initial ramp-up of new brownfield beds and newly acquired assets.
- Regulatory and execution delays in large greenfield approvals (Thane, Shaheed Path).
Key Highlights
Network gross revenue grew 16% YoY to ₹2,982 crore; Operating EBITDA rose 15% YoY to ₹704 crore with a 24.8% margin.
ARPOB expanded 5% YoY to ₹81,900 with network occupancy above 75% despite a 13% increase in operational bed capacity.
Board approved ₹425 crore brownfield expansion at Max Vaishali to add 202 beds (commissioning before FY30).
Net debt stood at ₹2,384 crore (net debt-to-EBITDA remains <1x) after deploying ₹386 crore on acquisitions in the quarter.
👀 What to Watch
Monitor the phased commercialization of the 500-bed Sector 56 Gurgaon hospital by year-end and the turnaround timeline for the newly acquired Bhubaneswar hospital.
₹425 Cr Capex for Vaishali Expansion and Strategic Entry into Medical Education
Max Healthcare has approved a ₹425 crore capital expenditure to expand its Vaishali facility, adding approximately 250 beds by November 2029. The company is also pivoting strategically to explore setting up medical colleges, following revised National Medical Commission (NMC) guidelines. Management has been strengthened with the appointment of Ajay Vij as Chief Supply Chain Officer and Pawan Kumar Marella as Chief Experience & Brand Officer. These moves support the company's stated goal of doubling its bed capacity over the next five years, backed by high current network occupancy of over 75%.
Confidence: HIGH
What changedThe company has committed to a new brownfield expansion in the NCR region and formally decided to enter the medical education sector.
Why it mattersWith occupancy exceeding 75%, Max Health needs additional beds to maintain growth; the medical college entry represents a significant strategic diversification into a regulated but synergistic vertical.
Expansion Capex: ₹425 CrCapex vs Net Worth: ~4.75%Total Beds to be Added: 250Network Occupancy (Q1 FY27): >75%Target Commissioning Date: November 2029
📅 Short termThe market is likely to react positively to the expansion news and the high occupancy levels, though the long gestation of the capex (2029) limits immediate EPS impact.
📈 Long termStructural growth remains intact as the company executes its plan to double capacity; medical colleges could provide a competitive advantage in clinical talent acquisition.
⚠ Risk flags
🔬 Flagged for deeper Multibagger analysis — view briefs →
- Execution risk given the 3-year construction timeline
- Regulatory risks associated with medical education
- Continued high concentration in the Delhi-NCR region
Key Highlights
₹425 crore investment approved for 'Tower 3' at Max Vaishali to add ~202 census and 48 non-census beds.
Network-wide occupancy remained high at >75% during Q1 FY27, necessitating capacity additions.
In-principle approval granted to evaluate setting up medical colleges/institutions under new NMC regulations.
Appointment of two new Senior Management Personnel (SMP) from Fortis and Unilever backgrounds.
The Vaishali expansion project is slated for commissioning by November 2029.
👀 What to Watch
Watch for the execution timeline of the Vaishali expansion and further clarity on the business model for the proposed medical colleges, which could serve as a long-term talent pipeline.
Max Healthcare Q1 Revenue up 16% to ₹2,982 Cr; ₹425 Cr Capex Approved for Vaishali
Max Healthcare reported a 16% YoY revenue growth to ₹2,982 Cr for Q1 FY27, driven by a 10% increase in occupied bed days and a 5% rise in ARPOB to ₹81.9k. While Operating EBITDA grew 15% to ₹704 Cr, PAT growth was limited to 3% (₹357 Cr) due to higher depreciation and finance costs from newly commissioned capacities. The company aggressively expanded its footprint, completing the ₹298 Cr acquisition of Kalinga Hospital (Bhubaneswar) and approving a new ₹425 Cr brownfield expansion in Vaishali. Net debt rose to ₹2,384 Cr following acquisition payouts and ongoing capex.
Confidence: HIGH
What changedThe company has moved from planning to execution on its regional diversification strategy with the Bhubaneswar acquisition and the Pune land parcel, while initiating a new brownfield project in Vaishali.
Why it mattersThe expansion is critical to reducing the company's 75-78% revenue concentration in Delhi-NCR and achieving its goal of doubling bed capacity over five years.
Q1 Gross Revenue: ₹2,982 CrQ1 PAT: ₹357 CrVaishali Capex vs Net Worth: ~4.75%ARPOB: ₹81.9kNet Debt: ₹2,384 CrOccupancy: 75%
📅 Short termThe stock may see positive sentiment from robust top-line growth and expansion updates, though the muted PAT growth due to front-loaded expansion costs might temper immediate gains.
📈 Long termThe structural growth story remains strong as the company executes its bed-doubling strategy and scales asset-light verticals like Max Lab and Max@Home.
⚠ Risk flags
🔬 Flagged for deeper Multibagger analysis — view briefs →
- Concentration risk in Delhi-NCR
- Rising finance costs and depreciation impacting net margins
- Execution risk for long-dated projects like Vaishali (FY30)
Key Highlights
Gross Revenue grew 16% YoY to ₹2,982 Cr, with ARPOB reaching ₹81.9k.
Operational bed capacity increased to 5,379 beds, a net addition of 630 beds compared to June 2025.
Approved ₹425 Cr capex for a 202-bed brownfield tower at MSSH Vaishali, slated for Q4 FY30.
Completed acquisition of 58.28% stake in Kalinga Hospital Limited for ~₹298 Cr.
Max Lab and Max@Home segments grew 20% and 32% YoY respectively, showing strong non-hospital momentum.
👀 What to Watch
Investors should monitor the occupancy ramp-up at the newly operationalized 202 beds in Max Smart and the integration efficiency of the Bhubaneswar acquisition. Watch for the impact of the foray into medical education on long-term capital allocation.
Max Healthcare Q1 Revenue up 16% to ₹2,982 Cr; EBITDA rises 15% to ₹704 Cr
Max Healthcare reported a 16% YoY revenue growth to ₹2,982 Cr for Q1 FY27, driven by a 10% increase in occupied bed days and a 5% rise in ARPOB to ₹81.9k. While Operating EBITDA grew 15% to ₹704 Cr, PAT growth was muted at 3% (₹357 Cr) due to higher depreciation and finance costs from newly commissioned capacities. The company aggressively expanded its footprint by acquiring a controlling stake in Kalinga Hospital (Bhubaneswar) and Yerawada Properties (Pune). Additionally, the board approved a ₹425 Cr capex for a 202-bed expansion at Vaishali and an in-principle foray into medical education.
Confidence: HIGH
What changedMax Healthcare reported its Q1 FY27 results, completed two strategic acquisitions in Bhubaneswar and Pune, and announced a new brownfield expansion in Vaishali.
Why it mattersThe results demonstrate the company's ability to maintain high ARPOB while scaling capacity. The foray into medical education is a strategic move to secure a long-term pipeline of clinical talent, addressing a key industry bottleneck.
Q1 Gross Revenue: ₹2,982 CrNetwork Operating EBITDA: ₹704 CrARPOB: ₹81.9kVaishali Capex vs TTM Revenue: ~5.1%Net Debt: ₹2,384 CrOccupancy: 75%
📅 Short termThe stock may see positive sentiment due to strong revenue and EBITDA growth, though the muted PAT growth due to expansion costs might temper the reaction.
📈 Long termThe company remains on track to double its bed capacity over 5 years. The expansion into non-metro markets like Bhubaneswar and the foray into medical education are structural positives for long-term growth.
⚠ Risk flags
🔬 Flagged for deeper Multibagger analysis — view briefs →
- Rising net debt (up ₹476 Cr in one quarter)
- Margin pressure from commissioning new brownfield capacities
- Execution risk in the new medical education vertical
Key Highlights
Gross Revenue grew 16% YoY to ₹2,982 Cr, representing ~35.6% of TTM revenue in a single quarter.
ARPOB increased 5% YoY to ₹81.9k, maintaining industry-leading realizations.
Operational bed capacity increased by 630 beds YoY to 5,379 beds as of June 2026.
Acquired 58.28% stake in Kalinga Hospital for ~₹298 Cr, marking entry into Odisha.
Approved ₹425 Cr capex for a new 202-bed tower at MSSH Vaishali, expected by Q4 FY30.
👀 What to Watch
Monitor the integration of the Bhubaneswar acquisition and the ramp-up of the 202 operationalized beds at Max Smart. Watch for further details on the medical education foray, as this represents a new capital allocation vertical.
₹425 Cr Capex for Vaishali Expansion and Entry into Medical Education
Max Healthcare has approved a ₹425 crore capital expenditure to expand its Vaishali facility by adding ~250 beds (202 census and 48 non-census), nearly doubling the unit's current 387-bed capacity. The expansion is driven by high network utilization of over 75% in Q1 FY27 and is expected to be commissioned by November 2029. Strategically, the board also gave in-principle approval to explore setting up medical colleges, following revised NMC regulations. Management transitions include the appointment of new heads for Supply Chain and Brand Experience to support scaling operations.
Confidence: HIGH
What changedThe company has committed to a specific ₹425 Cr expansion at Vaishali and formally pivoted to explore medical education as a new business vertical.
Why it mattersThe expansion addresses immediate capacity constraints in the high-demand Ghaziabad/UP region, while medical education offers a long-term strategic hedge for clinical talent sourcing.
Vaishali Capex: ₹425 CrCapex vs TTM Revenue: ~5.1%Total Beds to be Added: ~250Network Utilization (Q1 FY27): >75%Commissioning Target: November 2029
📅 Short termThe market is likely to view the continued capacity expansion and high utilization levels positively, though the long commissioning timeline means immediate revenue impact is nil.
📈 Long termStructural growth remains intact as the company executes its plan to double bed capacity; entry into medical education could improve long-term operational moats.
⚠ Risk flags
🔬 Flagged for deeper Multibagger analysis — view briefs →
- Execution risk given the 3-year+ construction timeline
- Regulatory approvals required for medical college entry
- Potential debt increase for financing
Key Highlights
₹425 Crore approved for 'Tower 3' construction at Max Super Speciality Hospital, Vaishali.
Addition of ~250 beds (202 census, 48 non-census) to the existing 387-bed Vaishali facility.
Network-wide capacity utilization reported at >75% for the quarter ended June 30, 2026.
Projected commissioning date for the new Vaishali capacity is November 2029.
In-principle approval to evaluate setting up medical colleges/institutions under new NMC norms.
👀 What to Watch
Watch for the detailed feasibility study on medical colleges and the quarterly progress of the Vaishali brownfield expansion against the 2029 timeline.
Max Healthcare Targets 10,000+ Beds by FY30; Increases Dividend to 20%
Max Healthcare confirmed its long-term strategy to double its bed capacity to over 10,000 by FY30, up from the current 6,000+ beds across 21 facilities. The company recently entered the Eastern India market by acquiring a 58.28% stake in Kalinga Hospital (Bhubaneswar). Management increased the dividend from 15% to 20% for FY26 but explicitly ruled out stock splits or bonus issues, citing adequate liquidity with 97.32 crore shares outstanding. International business is reportedly growing faster than overall revenue, supported by a new office in the UK to tap into medical tourism.
Confidence: HIGH
What changedThe company has formalized its FY30 capacity target and increased its dividend payout while clarifying its stance against share splits/bonuses.
Why it mattersThe expansion plan is critical to reducing the company's 75-78% revenue concentration in the Delhi-NCR region and maintaining its 15-20% expected growth rate.
FY30 Bed Capacity Target: 10,000+Current Bed Capacity: 6,000+Kalinga Hospital Stake: 58.28%Dividend Increase: 20% (from 15%)Total Patients Treated (FY26): 40 Lakh+Shares Outstanding: 97.32 Cr
📅 Short termThe transcript reinforces existing growth plans; no immediate stock price catalyst is expected as most details were previously disclosed in the annual report.
📈 Long termThe structural shift toward a 10,000-bed network and expansion into medical tourism (UK office) supports the high P/E valuation of 72.8, provided execution remains on track.
⚠ Risk flags
- Geographic concentration (75-78% in Delhi-NCR)
- Execution risk of doubling capacity within 4 years
Key Highlights
Targeting a network capacity of over 10,000 beds by FY30, nearly doubling current levels.
Acquired a 58.28% stake in Kalinga Hospital Limited (250 beds), marking entry into Eastern India.
Dividend payout increased to 20% from 15% in the previous year.
Current operations include 21 facilities with 6,000+ beds and 40,000+ professionals.
International business growth is currently outpacing the company's overall revenue growth rate.
👀 What to Watch
Monitor the quarterly execution of the bed expansion pipeline toward the 10,000-bed target and the integration of the Bhubaneswar acquisition. Watch for sustained ARPOB growth as the company expands into non-metro markets like Lucknow and Nagpur.
Max Healthcare 25th AGM: ₹2 Dividend Approved and Registered Office Shifted to Haryana
Max Healthcare Institute Limited concluded its 25th Annual General Meeting on July 30, 2026, where shareholders approved a final dividend of ₹2 per share (20% of face value). The Chairman reaffirmed the company's strategic goal to nearly double its bed capacity over the next five years through organic growth and M&A. Key updates included the post-FY26 acquisition of a 58.28% stake in Kalinga Hospital (Bhubaneswar) and the commissioning of new towers in Mohali, Mumbai, and Saket. Shareholders also approved shifting the registered office from Maharashtra to Haryana.
Confidence: HIGH
What changedShareholders have formally ratified the FY26 financial results, the dividend payout, and the administrative relocation of the company's registered office to Haryana.
Why it mattersThe AGM confirms management's commitment to aggressive capacity expansion and geographic diversification beyond its 75-78% Delhi-NCR concentration. The office shift to Haryana may align the legal seat closer to its primary operational hub.
Final Dividend: ₹2 per shareDividend Yield: 0.18%Stake in Kalinga Hospital: 58.28%Bed Capacity Target: Double in 5 yearsAGM Attendance: 160 members
📅 Short termThe stock is likely to remain stable as the AGM proceedings were largely in line with expectations, with the dividend providing a minor yield support.
📈 Long termThe structural growth story remains focused on the 5-year capacity doubling plan and de-risking from Delhi-NCR through expansions in Mumbai, Mohali, and Bhubaneswar.
⚠ Risk flags
- High concentration risk (75-78% revenue) in Delhi-NCR
- Intense competition in Noida and Mumbai markets
Key Highlights
Approved a final dividend of ₹2 per equity share for FY 2025-26
Reaffirmed long-term ambition to nearly double bed capacity over the next 5 years
Confirmed acquisition of 58.28% stake in Kalinga Hospital Limited (Bhubaneswar) post-FY26
Approved shifting the registered office from the State of Maharashtra to the State of Haryana
160 members attended the meeting via video conferencing
👀 What to Watch
Investors should monitor the execution timeline for the bed-doubling strategy and the operational integration of the newly acquired Bhubaneswar facility. The dividend payout will follow the record date established in the AGM notice.
Max Healthcare acquires 50.22% economic stake in YPPL for ~450-bed Pune hospital
Max Healthcare has completed the first tranche of its acquisition of Yerawada Properties Private Limited (YPPL), securing 100% voting rights and ~50.22% economic interest. This move officially makes YPPL a subsidiary and is a critical step toward establishing a new ~450-bed super specialty hospital in Pune. The acquisition follows a step-up model, where full economic ownership will be achieved upon milestones such as the grant of an occupancy certificate for the hospital. This expansion aligns with the company's stated strategy to double its bed capacity over the next five years.
Confidence: HIGH
What changedMax Healthcare has moved from an agreement stage to actual ownership of YPPL, gaining control of the land and entity required for its Pune expansion.
Why it mattersThis acquisition facilitates entry into the Pune market, helping the company de-risk from its 75-78% revenue concentration in Delhi-NCR while adding significant bed capacity to its current network of 22 facilities.
Economic interest acquired: ~50.22%Voting rights acquired: 100%Planned bed capacity: ~450 bedsCurrent network facilities: 22Tranche completion date: June 30, 2026
📅 Short termThe market is likely to view this as a positive execution of the company's growth strategy, though immediate financial impact will be limited until the hospital is operational.
📈 Long termStrategically significant as it establishes a footprint in a high-ARPOB market like Pune, contributing to the long-term goal of doubling capacity and diversifying revenue geographically.
⚠ Risk flags
🔬 Flagged for deeper Multibagger analysis — view briefs →
- Execution risk related to hospital construction
- Regulatory delays in obtaining occupancy certificates
- Gestation period for new hospital to reach EBITDA breakeven
Key Highlights
Acquired 100% of Class A equity shares, representing 100% voting rights in YPPL
Secured ~50.22% economic interest in the first tranche of the Share Purchase Agreement
Planned development of a ~450-bedded super speciality hospital on land owned by YPPL in Pune
YPPL has officially become a subsidiary of Max Healthcare as of June 30, 2026
The acquisition is part of a step-up arrangement first initiated in December 2025
👀 What to Watch
Investors should monitor the construction timeline for the Pune facility and the specific regulatory milestones, such as the occupancy certificate, which will trigger the final increase in economic stake.
Max Healthcare Announces ₹2.00 Dividend; Sets July 3, 2026, as Record Date
Max Healthcare Institute Limited has recommended a final dividend of ₹2.00 per equity share (20% of face value) for the financial year ended March 31, 2026. The company has fixed July 3, 2026, as the record date to determine eligibility for this dividend, which is subject to approval at the upcoming AGM. The 25th Annual General Meeting is scheduled for July 30, 2026, via video conferencing. Detailed tax deduction (TDS) guidelines have been issued, requiring shareholders to update PAN and submit relevant forms to avail lower tax rates.
Key Highlights
Recommended a final dividend of ₹2.00 per equity share with a face value of ₹10 each for FY 2025-26.
Fixed Friday, July 3, 2026, as the 'Record Date' for determining members entitled to the final dividend.
The 25th Annual General Meeting (AGM) is scheduled to be held on Thursday, July 30, 2026.
TDS of 10% will be deducted for resident shareholders with valid PAN if the dividend exceeds ₹10,000.
Non-resident shareholders can claim beneficial Tax Treaty rates by providing a Tax Residency Certificate (TRC) and Form 41.
👀 What to Watch
Investors interested in the dividend should ensure they hold the stock before the record date of July 3, 2026. Shareholders should also promptly submit tax-related documents like Form 121 or TRC to the RTA to optimize their tax liability.
Max Healthcare Sets July 3, 2026 as Record Date for ₹2.00 Final Dividend
Max Healthcare Institute Limited has announced a final dividend of ₹2.00 per equity share (20% of face value) for the financial year ended March 31, 2026. The company has fixed July 3, 2026, as the record date to determine shareholder eligibility for this payout. The dividend is subject to shareholder approval at the 25th Annual General Meeting scheduled for July 30, 2026. The company also detailed tax deduction (TDS) protocols, noting a 10% rate for residents with valid PANs and higher rates for non-compliant accounts.
Key Highlights
Recommended final dividend of ₹2.00 per equity share with a face value of ₹10 (20%).
Record date for dividend entitlement is Friday, July 3, 2026.
25th Annual General Meeting (AGM) to be held on July 30, 2026, via video conferencing.
TDS of 10% for resident individuals if total dividend exceeds ₹10,000, provided PAN is linked with Aadhaar.
Non-resident shareholders may avail Tax Treaty benefits by submitting Tax Residency Certificates (TRC) and Form 41.
👀 What to Watch
Investors interested in the dividend should ensure they hold the shares in their demat account before the ex-dividend date. Shareholders should also verify that their PAN is correctly linked with Aadhaar to avoid a higher TDS rate of 20%.
Max Healthcare Q4 FY26: Revenue Up 10% to ₹2,664 Cr; Plans ₹1,400 Cr Lucknow Expansion
Max Healthcare reported a 10% YoY revenue growth in Q4 FY26 to ₹2,664 crore, with full-year PAT rising 22% to ₹1,631 crore. The company is aggressively expanding, having commissioned 20% additional brownfield capacity and announcing a new ₹1,400 crore greenfield project in Lucknow. Despite a temporary dip in oncology revenue due to drug discontinuation, occupancy remained strong at over 75%. Management expects significant operating leverage as new capacities in Gurgaon and other locations ramp up in FY27.
Key Highlights
Network gross revenue for FY26 reached ₹10,538 crore, a 16% YoY increase from the previous year.
Operating EBITDA for Q4 stood at ₹682 crore with a healthy margin of 26.8% and EBITDA per bed of ₹73 lakh.
Completed acquisition of Kalinga Hospital (250 beds) in Bhubaneswar, marking entry into Eastern India.
Board approved ₹1,400 crore investment for a new 700-bed greenfield hospital at Shaheed Path, Lucknow.
Net debt-to-EBITDA ratio remains conservative at less than 1, with free cash flow generation of ₹581 crore in Q4.
👀 What to Watch
Investors should focus on the successful ramp-up of the 20% newly added brownfield capacity and the upcoming Gurgaon greenfield commissioning. The company's aggressive expansion funded by strong internal accruals makes it a robust long-term play in the healthcare sector.
Max Healthcare Reports 33% EBITDA CAGR and 6,000+ Bed Capacity at UBS Conference
Max Healthcare Institute Limited showcased its robust growth trajectory at the UBS Asian Investment Conference, highlighting a 5-year EBITDA CAGR of 33% and a revenue CAGR of 22%. The company currently operates over 6,000 beds across 21 facilities, with a significant 73% concentration in metro cities. For FY26, the company reported a healthy occupancy rate of 76% and a Return on Capital Employed (ROCE) of 23%, supported by a market capitalization of ₹1.0 Lakh Cr.
Key Highlights
Achieved a 5-year EBITDA CAGR of 33% and Revenue CAGR of 22% as of FY26.
Total bed capacity exceeds 6,000 across 21 facilities with 76% occupancy recorded in FY26.
Strong institutional ownership with FIIs and DIIs collectively holding approximately 71.7% of the company.
Aggressive expansion through acquisitions in Lucknow (Sahara Hospital), Nagpur (Alexis), and Bhubaneshwar (KHL).
Reported a high ROCE of 23% and a Market Cap CAGR of 36% between April 2021 and May 2026.
👀 What to Watch
Investors should focus on the company's ability to maintain high occupancy and ROCE as it integrates new acquisitions in Lucknow and Bhubaneshwar. The stock remains a strong long-term play in the premium healthcare segment given its aggressive brownfield expansion pipeline.
Max Healthcare Wins CCI Case; No Abuse of Dominant Position Found in Pricing Probe
The Competition Commission of India (CCI) has ruled in favor of Max Healthcare, closing a long-standing investigation into alleged unfair pricing practices. The probe, which originated from a 2018 order, examined the pricing of medicines, packages, and consumables across six Max Network hospitals in Delhi. The CCI rejected the Director General's findings of abuse of dominant position under Section 4 of the Competition Act, 2002. This resolution removes a significant regulatory overhang and potential financial liability, as the matter is now closed with no adverse orders.
Key Highlights
CCI passed orders on May 21, 2026, in favor of multiple Max Network hospitals.
The investigation involved 6 Max Network hospitals regarding pricing of medicines and consumables.
The CCI rejected the Director General's (DG) findings of abuse of dominant position.
The matter is officially closed with no penalties or adverse financial impact on the company.
The ruling concludes a legal process that has been ongoing since August 2018.
👀 What to Watch
This is a positive development that eliminates a major regulatory risk and potential financial penalty. Investors should view this as a removal of a legal cloud, allowing the market to focus on the company's operational performance.
Max Healthcare to add 712 beds in Lucknow; recommends ₹2 per share dividend
Max Healthcare has approved a significant capacity expansion with the construction of a 712-bed super specialty hospital in Lucknow. The Board also recommended a final dividend of ₹2 per equity share (20% of face value) for FY 2025-26. Additionally, the company is streamlining its corporate structure by shifting its registered office to Gurugram and re-classifying a promoter entity to the public category. These developments, alongside the FY26 financial results, signal strong growth intent and operational consolidation.
Key Highlights
Approved Phase-I construction of Max Super Specialty Hospital in Lucknow with ~712 census beds on a 5-acre land parcel.
Recommended a final dividend of ₹2 per equity share for the financial year ended March 31, 2026.
Approved re-classification of Radiant Life Care Hospital Foundation from 'Promoter Group' to 'Public' category.
Shifting of the registered office from Mumbai, Maharashtra to Gurugram, Haryana, subject to shareholder approval.
Re-appointment of Mr. Anil Kumar Bhatnagar as Non-Executive Director for a further period of 3 years.
👀 What to Watch
The 712-bed expansion in Lucknow provides strong long-term growth visibility in a key North Indian market. Investors should remain positive on the stock given the aggressive capacity addition and consistent dividend payout.
Max Healthcare Recommends ₹2 Dividend and Approves 712-Bed Lucknow Hospital Expansion
Max Healthcare has announced a final dividend of ₹2 per share for FY26, representing 20% of its face value. A major growth milestone was reached with the board's approval for a new 712-bed hospital facility in Lucknow, situated on a 5-acre land parcel. The company is also undergoing a shareholding structure change as Radiant Life Care Hospital Foundation moves from the 'Promoter Group' to the 'Public' category. Additionally, the registered office is being shifted from Mumbai to Gurugram to streamline operations.
Key Highlights
Recommended a final dividend of ₹2 per equity share for the financial year 2025-26.
Approved Phase-I construction of Max Super Specialty Hospital in Lucknow with a capacity of ~712 beds.
Radiant Life Care Hospital Foundation re-classified from 'Promoter Group' to 'Public' category.
Re-appointed Mr. Anil Kumar Bhatnagar as Non-Executive Director for a 3-year term starting October 2026.
Shifting of registered office from Mumbai, Maharashtra to Gurugram, Haryana approved subject to AGM.
👀 What to Watch
Investors should view the massive 712-bed expansion in Lucknow as a strong long-term growth driver for the company's footprint. The dividend and promoter re-classification are also positive indicators of corporate maturity and governance.
Max Healthcare Q4 Results: ₹2 Dividend & New 712-Bed Hospital in Lucknow
Max Healthcare has recommended a final dividend of ₹2 per share for FY26 following its board meeting. A major highlight is the approval for a new ~712-bed hospital project in Lucknow, marking a significant capacity expansion. The board also approved shifting the registered office to Gurugram and the re-appointment of Mr. Anil Kumar Bhatnagar as a director. Furthermore, a promoter group entity is seeking re-classification to the public category, indicating a potential change in shareholding structure.
Key Highlights
Final dividend of ₹2 per equity share (20% of face value) recommended for FY 2025-26.
New hospital construction approved in Shaheed Path, Lucknow with ~712 census beds on 5-acre land.
Registered office to be shifted from Mumbai, Maharashtra to Gurugram, Haryana, subject to approvals.
Re-appointment of Mr. Anil Kumar Bhatnagar as Non-Executive Director for a 3-year term starting October 2026.
Radiant Life Care Hospital Foundation to be re-classified from 'Promoter Group' to 'Public' category.
👀 What to Watch
The aggressive bed-capacity expansion in Lucknow is a positive signal for future revenue growth; long-term investors should maintain their positions. Monitor the detailed financial results for specific margin and PAT growth trends.
Max Healthcare Q4: ₹2 Dividend Declared, New 712-Bed Lucknow Hospital Approved
Max Healthcare Institute Limited announced its Q4 and FY26 financial results, recommending a final dividend of ₹2 per equity share (20% of face value). The Board approved a significant expansion project for a ~712-bed hospital in Lucknow on a 5-acre land parcel. Additionally, the company is shifting its registered office from Mumbai to Gurugram and has approved the re-classification of Radiant Life Care Hospital Foundation from 'Promoter Group' to 'Public' category.
Key Highlights
Recommended a final dividend of ₹2 per equity share (20% of face value) for the financial year 2025-26.
Approved Phase-I construction of a new ~712-bed Max Super Specialty Hospital at Shaheed Path, Lucknow.
Shifting registered office from Mumbai, Maharashtra to Gurugram, Haryana, pending shareholder approval.
Approved the re-classification of Radiant Life Care Hospital Foundation to the 'Public' category.
Re-appointed Mr. Anil Kumar Bhatnagar as Non-Executive and Non-Independent Director for a 3-year term.
👀 What to Watch
Investors should note the significant capacity expansion in Lucknow as a long-term growth driver and the ₹2 dividend as a positive yield signal. Monitor the upcoming AGM for final approvals on the dividend and the registered office relocation.
Max Healthcare to Build 712-Bed Lucknow Hospital; Declares ₹2 Dividend
Max Healthcare has announced a major expansion with the approval of a 712-bed hospital in Lucknow, significantly boosting its future capacity. The board also recommended a final dividend of ₹2 per share for FY26, rewarding shareholders. Administratively, the company is shifting its registered office from Mumbai to Gurugram and reclassifying a promoter entity to the public category. These developments reflect a mix of aggressive infrastructure growth and corporate restructuring.
Key Highlights
Recommended a final dividend of ₹2 per equity share (20% of face value) for FY 2025-26.
Approved construction of Phase-I of a new hospital in Lucknow with a capacity of ~712 census beds.
Proposed shifting of the registered office from Mumbai, Maharashtra to Gurugram, Haryana.
Approved re-classification of Radiant Life Care Hospital Foundation from 'Promoter Group' to 'Public' category.
Re-appointed Mr. Anil Kumar Bhatnagar as Non-Executive Director for a 3-year term starting October 2026.
👀 What to Watch
Investors should monitor the execution timelines of the Lucknow hospital project as it represents a significant capacity addition. The dividend and office consolidation are positive signs of financial health and operational streamlining.
